Drug Profile
Research programme: amyotrophic lateral sclerosis vaccines - Amorfix
Latest Information Update: 18 Dec 2014
Price :
$50
*
At a glance
- Originator Amorfix Life Sciences
- Developer ProMIS Neurosciences
- Class Vaccines
- Mechanism of Action Superoxide dismutase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Suspended Amyotrophic lateral sclerosis
Most Recent Events
- 08 Aug 2014 Suspended - Preclinical for Amyotrophic lateral sclerosis in Canada (Parenteral)
- 13 Aug 2013 Research programme: amyotrophic lateral sclerosis vaccines - Amorfix is available for licensing as of 13 August 2013. http://www.amorfix.com
- 30 Jun 2013 Amyotrophic lateral sclerosis vaccines no longer licensed to Pan-Provincial Vaccine Enterprise